A deal will include milestone payments to manage risk along the way. The deal might be 500M, but will only be a small amount up front, with further payments with positive P3 results and FDA marketing approval etc. So they will only pay the full amount for a drug that makes it to market.
Royalties will form an important part of the deal providing Neuren with a long term funding model to support other developments and use applications (eg TBI).
We are lucky to have Dr T with so much experience in this area.
A deal will include milestone payments to manage risk along the...
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.40 |
Change
1.130(8.52%) |
Mkt cap ! $1.840B | |||
| Open | High | Low | Value | Volume |
| $13.80 | $14.45 | $13.53 | $15.04M | 1.062M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 871 | $14.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.42 | 3650 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |